New data reinforce the effectiveness of Viberzi to treat the symptoms associated with IBS-D
Viberzi proven safe and effective in patients who reported inadequate response to prior loperamide use.
Allergan has announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase III studies (IBS-3001 and IBS-3002), which evaluated the efficacy and safety of Viberzi in nearly 2,500 IBS-D patients, of whom 36% reported use of loperamide in the 12 months prior to study randomization. These data demonstrate Viberzi (eluxadoline) safely and effectively treats the IBS-D symptoms of abdominal pain and diarrhea irrespective of prior use of loperamide. These analyses also demonstrated efficacy and safety in patients with loperamide rescue medication use compared to the overall population during the two studies.
"Irritable bowel syndrome with diarrhea is a health concern that affects approximately 16 million people, and despite the use of over-the-counter medications, many patients experience debilitating symptoms associated with the syndrome and often cycle through several options with little to no relief," said lead author Brian E. Lacy, MD, PhD, Division of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center. "These results further support the use of eluxadoline to provide significant and effective relief from abdominal pain and diarrhea, two of the most common symptoms affecting those suffering with IBS-D, regardless of prior treatment experience."
Among patients who reported prior loperamide use with inadequate symptom control, a significantly greater proportion of patients treated with eluxadoline were composite responders over weeks 1-12 compared with those treated with placebo (eluxadoline 100 mg: 27.0% and 75 mg: 26.3% versus placebo 12.7%). The most commonly reported adverse events are consistent with the known safety profile of eluxadoline, which were nausea, abdominal pain, constipation and headache.
"These results continue to build on the robust clinical profile that has already been established, and further underscores Viberzi as a safe and effective treatment option for patients suffering from inadequate symptom control associated with a commonly used treatment for IBS-D," said David Nicholson, Chief Research & Development Officer, Allergan.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance